These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 14708697)

  • 1. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon.
    Brunetto MR; Oliveri F; Colombatto P; Coco B; Ciccorossi P; Bonino F
    J Hepatol; 2003; 39 Suppl 1():S164-7. PubMed ID: 14708697
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon.
    Cooksley G
    J Hepatol; 2003; 39 Suppl 1():S143-5. PubMed ID: 14708693
    [No Abstract]   [Full Text] [Related]  

  • 3. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
    Hui CK; Lai LS; Lam P; Zhang HY; Fung TT; Lai ST; Wong WM; Lo CM; Fan ST; Leung N; Lau GK;
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1171-8. PubMed ID: 16611278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of efficacy of pegylated interferon alfa-2a or interferon alfa-2b combination therapy with nucleus(t)ide analogues in HBeAg positive chronic hepatitis B patients].
    Wang SQ; Xu KJ; Wu JZ; Liu XS; Luo TT; Yang RG; Geng XX; Huang RG; Lin JM; Jiang N
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):785-6. PubMed ID: 22423366
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs.
    Janssen HL; Lau GK
    Hepatology; 2005 Dec; 42(6):1459; author reply 1459-60. PubMed ID: 16317685
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
    Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
    J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological agents for the treatment of chronic hepatitis B].
    Sánchez-Tapias JM
    Gastroenterol Hepatol; 2008 Mar; 31(3):120-8. PubMed ID: 18341843
    [No Abstract]   [Full Text] [Related]  

  • 8. Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
    Cooksley G
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):12-3. PubMed ID: 16265091
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Orlent H
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16224825
    [No Abstract]   [Full Text] [Related]  

  • 10. The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment.
    Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Li ZZ; Wu SL; Liu RY; Chang M; Hu LP; Hua WH; Song SJ; Wan G; Xie Y
    Biomed Environ Sci; 2017 Mar; 30(3):177-184. PubMed ID: 28427487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eye.
    Dienstag JL
    Am J Gastroenterol; 2010 Aug; 105(8):1770-2. PubMed ID: 20686463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatitis B with interferon and combination therapy.
    Cooksley WG
    Clin Liver Dis; 2004 May; 8(2):353-70. PubMed ID: 15481344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
    Suh DJ; Lee HC; Byun KS; Cho M; Kweon YO; Tak WY; Chon CY; Koh KC; Lee YS
    Antivir Ther; 2013; 18(6):765-73. PubMed ID: 23900457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interferon therapy for chronic hepatitis B].
    Tang WL; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):726-9. PubMed ID: 19874685
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment with interferons (including pegylated interferons) in patients with hepatitis B.
    Cooksley WG
    Semin Liver Dis; 2004; 24 Suppl 1():45-53. PubMed ID: 15192801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Discussions the therapy strategy of chronic hepatitis B by analyzing the therapeutics course of a chronic hepatitis B patient].
    Yang LQ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):709-10. PubMed ID: 19785967
    [No Abstract]   [Full Text] [Related]  

  • 19. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pegylated interferon alpha in the treatment of chronic hepatitis B in HBe negative patients].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2006; 60(1):105-8. PubMed ID: 16758747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.